Incidence of febrile neutropenia (FN) with pegfilgrastim (PF) on day of chemotherapy (D1) versus 24–72 hrs later (D2)

e20664 Background: Docetaxel, doxorubicin hydrochloride, and cyclophosphamide (TAC) is a commonly used adjuvant chemotherapy (C) regimen in patients (pts) with high risk breast cancer (BC). Pegfilgrastim (PF) is a long acting G-CSF known to decrease the risk of FN. It is typically given the day after C. Illinois CancerCare (ILCC) is a large oncology practice that provides cancer care to many communities in Illinois. For patients with limited access to medical care, in past PF has been given on same day as C. In this study we have compared the incidence of FN in pts who received PF on the same day as TAC (D1) versus those who received it 24–72 hrs after C (D2). Methods: All pts treated for BC at ILCC between 09/2004 and 08/2008, and received TAC and PF were deemed eligible. Logistic regression was used to analyze the association between incidence of FN and type of regimens. Results: Of the 56 eligible pts (55 females), mean age 52.9 yrs (range 27.8–84.8 yrs), 43 patients received PF on D1 and 13 pts receiv...